Details for Patent: 11,964,980

Which drugs does patent 11,964,980 protect, and when does it expire?

Patent 11,964,980 protects AYVAKIT and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 11,964,980

Title:	Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1- f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
Abstract:	Crystalline Forms of Compound (I):pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Inventor(s):	Joshua D. Waetzig, Gordon Wilkie
Assignee:	Blueprint Medicines Corp
Application Number:	US18/077,466
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 11,964,980

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-004	Jun 16, 2021		RX	Yes	No	11,964,980		Y	Y
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-005	Jun 16, 2021		RX	Yes	No	11,964,980		Y	Y
Blueprint Medicines	AYVAKIT	avapritinib	TABLET;ORAL	212608-001	Jan 9, 2020		RX	Yes	No	11,964,980		Y	Y

International Family Members for US Patent 11,964,980

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3136707
Canada	3296895
China	113966334